{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:02:35Z","timestamp":1790715755428,"version":"4.1.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"DOI":"10.1007\/s11845-026-04620-8","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:21:14Z","timestamp":1790666474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atopic dermatitis management: integrating disease mechanisms with precision medicine and nanotechnology-based targeted therapies"],"prefix":"10.1007","author":[{"given":"Iqra","family":"Nazeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4900-4497","authenticated-orcid":false,"given":"Hira","family":"Mubeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabiya","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"4","key":"4620_CR1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1542\/PIR.2016-0169","volume":"39","author":"AR Waldman","year":"2018","unstructured":"Waldman AR, Ahluwalia J, Udkoff J et al (2018) Atopic dermatitis. Pediatr Rev 39(4):180\u2013193. https:\/\/doi.org\/10.1542\/PIR.2016-0169","journal-title":"Pediatr Rev"},{"key":"4620_CR2","unstructured":"\u201cEczema Treatment Research | NIAID: National Institute of Allergy and Infectious Diseases.\u201d. https:\/\/www.niaid.nih.gov\/diseases-conditions\/eczema-treatment. Accessed 08 Feb 2026"},{"issue":"2","key":"4620_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.19580","volume":"184","author":"MR Laughter","year":"2021","unstructured":"Laughter MR and others (2021) The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990\u20132017. Br J Dermatol 184(2):304\u2013309. https:\/\/doi.org\/10.1111\/bjd.19580","journal-title":"Br J Dermatol"},{"issue":"4","key":"4620_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaip.2014.03.006","volume":"2","author":"T Czarnowicki","year":"2014","unstructured":"Czarnowicki T, Krueger JG, Guttman-Yassky E (2014) Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. J Allergy Clin Immunol Pract 2(4):371\u2013379. https:\/\/doi.org\/10.1016\/j.jaip.2014.03.006","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"4620_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/J.JACI.2013.08.031","volume":"132","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Hanifin JM (2013) Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 132(5):1132\u20131138. https:\/\/doi.org\/10.1016\/J.JACI.2013.08.031","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"4620_CR6","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/ALL.13320","volume":"73","author":"K Abuabara","year":"2018","unstructured":"Abuabara K, Yu AM, Okhovat JP et al (2018) The prevalence of atopic dermatitis beyond childhood: a systematic review and meta-analysis of longitudinal studies. Allergy Eur J Allergy Clin Immunol 73(3):696\u2013704. https:\/\/doi.org\/10.1111\/ALL.13320","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"4620_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACI.2009.05.039","author":"LS Fonacier","year":"2010","unstructured":"Fonacier LS, Dreskin SC, Leung DYM (2010) Allergic skin diseases. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/J.JACI.2009.05.039","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"4620_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/J.ANAI.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI and others (2021) Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy, Asthma Immunol 126(4):417-428.e2. https:\/\/doi.org\/10.1016\/J.ANAI.2020.12.020","journal-title":"Ann Allergy, Asthma Immunol"},{"key":"4620_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-3-319-64804-0_4","volume":"1027","author":"C Ahn","year":"2017","unstructured":"Ahn C, Huang W (2017) Clinical presentation of atopic dermatitis. Adv Exp Med Biol 1027:39\u201346. https:\/\/doi.org\/10.1007\/978-3-319-64804-0_4","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"4620_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.5863\/1551-6776-29.6.587","volume":"29","author":"J Jeskey","year":"2024","unstructured":"Jeskey J and others (2024) Atopic dermatitis: a review of diagnosis and treatment. J Pediatr Pharmacol Ther 29(6):587. https:\/\/doi.org\/10.5863\/1551-6776-29.6.587","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"4","key":"4620_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jaad.2016.05.028","volume":"75","author":"JP Kim","year":"2016","unstructured":"Kim JP, Chao LX, Simpson EL, Silverberg JI (2016) Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. J Am Acad Dermatol 75(4):681-687.e11. https:\/\/doi.org\/10.1016\/j.jaad.2016.05.028","journal-title":"J Am Acad Dermatol"},{"key":"4620_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22084130","author":"J Sroka-Tomaszewska","year":"2021","unstructured":"Sroka-Tomaszewska J, Trzeciak M (2021) Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS22084130","journal-title":"Int J Mol Sci"},{"key":"4620_CR13","unstructured":"House W (2022) Global Report on Atopic Dermatitis 2022 atopicdermatitisatlas.org International League of Dermatological Societies (ILDS) International League of Dermatological Societies. www.atopicdermatitisatlas.org. Accessed 05 Feb 2026"},{"issue":"5","key":"4620_CR14","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/J.JID.2023.10.019","volume":"144","author":"CF Schuler","year":"2024","unstructured":"Schuler CF, Tsoi LC, Billi AC et al (2024) Genetic and immunological pathogenesis of atopic dermatitis. J Invest Dermatol 144(5):954\u2013968. https:\/\/doi.org\/10.1016\/J.JID.2023.10.019","journal-title":"J Invest Dermatol"},{"issue":"7","key":"4620_CR15","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/S13555-024-01193-1","volume":"14","author":"F Libon","year":"2024","unstructured":"Libon F, Caron J, Nikkels AF (2024) Biomarkers in atopic dermatitis. Dermatol Ther (Heidelb) 14(7):1729\u20131738. https:\/\/doi.org\/10.1007\/S13555-024-01193-1","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"4620_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0301-0546(06)73535-2","volume":"34","author":"MT Montero Vega","year":"2006","unstructured":"Montero Vega MT (2006) New aspects on inflammation in allergic diseases. Allergol Immunopathol (Madr) 34(4):156\u2013170. https:\/\/doi.org\/10.1016\/S0301-0546(06)73535-2","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"3","key":"4620_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4172\/2155-9899.1000110","volume":"2","author":"EB Brandt","year":"2011","unstructured":"Brandt EB, Sivaprasad U (2011) Th2 cytokines and atopic dermatitis. J Clin Cell Immunol 2(3):110. https:\/\/doi.org\/10.4172\/2155-9899.1000110","journal-title":"J Clin Cell Immunol"},{"issue":"1","key":"4620_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/S41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber T (2022) Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov 21(1):21\u201340. https:\/\/doi.org\/10.1038\/S41573-021-00266-6","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"4620_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/NRMICRO.2017.157","volume":"16","author":"AL Byrd","year":"2018","unstructured":"Byrd AL, Belkaid Y, Segre JA (2018) The human skin microbiome. Nat Rev Microbiol 16(3):143\u2013155. https:\/\/doi.org\/10.1038\/NRMICRO.2017.157","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"4620_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","volume":"71","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF and others (2014) Guidelines of care for the management of atopic dermatitis: part 2: management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 71(1):116. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.023","journal-title":"J Am Acad Dermatol"},{"key":"4620_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.94667","author":"MLA Fern\u00e1ndez","year":"2025","unstructured":"Fern\u00e1ndez MLA et al (2025) Treatment-resistant atopic dermatitis in adulthood: a case report. Cureus. https:\/\/doi.org\/10.7759\/CUREUS.94667","journal-title":"Cureus"},{"key":"4620_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/JCM12103419","author":"GB Soares","year":"2023","unstructured":"Soares GB, Orfali RL, Averbach BL et al (2023) Atopic dermatitis in Latin America: considerations on epidemiology, clinical and laboratory features, ethnic\/racial variations, and therapeutic management. J Clin Med. https:\/\/doi.org\/10.3390\/JCM12103419","journal-title":"J Clin Med"},{"issue":"7","key":"4620_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/DDR.70161;CTYPE:STRING:JOURNAL","volume":"86","author":"M Xie","year":"2025","unstructured":"Xie M, Kong L, Li G et al (2025) Atopic dermatitis: updated insights into pathophysiology and emerging therapies. Drug Dev Res 86(7):e70161. https:\/\/doi.org\/10.1002\/DDR.70161;CTYPE:STRING:JOURNAL","journal-title":"Drug Dev Res"},{"key":"4620_CR24","doi-asserted-by":"publisher","first-page":"12889","DOI":"10.2147\/IJN.S487188","volume":"19","author":"MT El-Saadony","year":"2024","unstructured":"El-Saadony MT and others (2024) Green synthesis of zinc oxide nanoparticles: preparation, characterization, and biomedical applications - a review. Int J Nanomedicine 19:12889. https:\/\/doi.org\/10.2147\/IJN.S487188","journal-title":"Int J Nanomedicine"},{"issue":"4","key":"4620_CR25","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/S12668-020-00774-6","volume":"10","author":"SA Akintelu","year":"2020","unstructured":"Akintelu SA, Folorunso AS (2020) A review on green synthesis of zinc oxide nanoparticles using plant extracts and its biomedical applications. Bionanoscience 10(4):848\u2013863. https:\/\/doi.org\/10.1007\/S12668-020-00774-6","journal-title":"Bionanoscience"},{"issue":"8","key":"4620_CR26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28130","volume":"14","author":"BU Umar","year":"2022","unstructured":"Umar BU and others (2022) Management of atopic dermatitis: the role of tacrolimus. Cureus 14(8):e28130. https:\/\/doi.org\/10.7759\/cureus.28130","journal-title":"Cureus"},{"issue":"4","key":"4620_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/pai.12331","volume":"26","author":"T Luger","year":"2015","unstructured":"Luger T and others (2015) Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol 26(4):306. https:\/\/doi.org\/10.1111\/pai.12331","journal-title":"Pediatr Allergy Immunol"},{"issue":"5","key":"4620_CR28","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A et al (2020) Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy 75(5):1188. https:\/\/doi.org\/10.1111\/all.14151","journal-title":"Allergy"},{"key":"4620_CR29","doi-asserted-by":"publisher","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W (2021) The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 6(1): 100161. https:\/\/doi.org\/10.1038\/s41392-021-00791-1","DOI":"10.1038\/s41392-021-00791-1"},{"key":"4620_CR30","unstructured":"Iyengar L (2025) Atopic dermatitis: new and emerging treatments. Med Today"},{"issue":"4","key":"4620_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2025.501135","volume":"100","author":"D Hartmann","year":"2025","unstructured":"Hartmann D, Retamal C, Valenzuela F (2025) Precision medicine and Treat-to-Target approach in atopic dermatitis: enhancing personalized care and outcomes. An Bras Dermatol 100(4):501135. https:\/\/doi.org\/10.1016\/j.abd.2025.501135","journal-title":"An Bras Dermatol"},{"issue":"9","key":"4620_CR32","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1111\/all.16183","volume":"79","author":"S Nakajima","year":"2024","unstructured":"Nakajima S, Nakamizo S, Nomura T et al (2024) Integrating multi-omics approaches in deciphering atopic dermatitis pathogenesis and future therapeutic directions. Allergy Eur J Allergy Clin Immunol 79(9):2366\u20132379. https:\/\/doi.org\/10.1111\/all.16183","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"issue":"3","key":"4620_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/1346-8138.12321","volume":"41","author":"M Tamari","year":"2014","unstructured":"Tamari M, Hirota T (2014) Genome-wide association studies of atopic dermatitis. J Dermatol 41(3):213\u2013220. https:\/\/doi.org\/10.1111\/1346-8138.12321","journal-title":"J Dermatol"},{"issue":"3","key":"4620_CR34","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jaci.2023.01.012","volume":"151","author":"R Labrosse","year":"2023","unstructured":"Labrosse R, Haddad E (2023) Immunodeficiency secondary to biologics. J Allergy Clin Immunol 151(3):686\u2013690. https:\/\/doi.org\/10.1016\/j.jaci.2023.01.012","journal-title":"J Allergy Clin Immunol"},{"issue":"15","key":"4620_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158791","volume":"23","author":"J Afghani","year":"2022","unstructured":"Afghani J, Traidl-Hoffmann C, Schmitt-Kopplin P et al (2022) An overview of the latest metabolomics studies on atopic eczema with new directions for study. Int J Mol Sci 23(15):8791. https:\/\/doi.org\/10.3390\/ijms23158791","journal-title":"Int J Mol Sci"},{"issue":"12","key":"4620_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.semcdb.2023.04.005","volume":"154","author":"S Akhtar","year":"2024","unstructured":"Akhtar S and others (2024) Epigenetic control of inflammation in atopic dermatitis. Semin Cell Dev Biol 154(12):199\u2013207. https:\/\/doi.org\/10.1016\/j.semcdb.2023.04.005","journal-title":"Semin Cell Dev Biol"},{"key":"4620_CR37","doi-asserted-by":"publisher","first-page":"1404117","DOI":"10.3389\/fnut.2024.1404117","volume":"11","author":"R Wu","year":"2024","unstructured":"Wu R, Tian H, Zhao T et al (2024) A Mendelian randomization analysis of inflammatory skin disease risk due to mineral deficiencies. Front Nutr 11:1404117. https:\/\/doi.org\/10.3389\/fnut.2024.1404117","journal-title":"Front Nutr"},{"issue":"4","key":"4620_CR38","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/bjd.14566","volume":"175","author":"JEE Tott\u00e9","year":"2016","unstructured":"Tott\u00e9 JEE, van der Feltz WT, Hennekam M et al (2016) Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol 175(4):687\u2013695. https:\/\/doi.org\/10.1111\/bjd.14566","journal-title":"Br J Dermatol"},{"issue":"3","key":"4620_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/ACI.0000000000000820","volume":"22","author":"J Kim","year":"2022","unstructured":"Kim J, Ahn K (2022) Atopic dermatitis endotypes: knowledge for personalized medicine. Curr Opin Allergy Clin Immunol 22(3):153\u2013159. https:\/\/doi.org\/10.1097\/ACI.0000000000000820","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"4620_CR40","unstructured":"\u201cMind.Px Test For Plaque Psoriasis - Mindera Health\u201d. https:\/\/minderahealth.com\/tag\/mind-px-test-for-plaque-psoriasis\/. Accessed 05 Feb 2026"},{"key":"4620_CR41","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3751","author":"M De Bruin-Weller","year":"2021","unstructured":"De Bruin-Weller M and others (2021) Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. https:\/\/doi.org\/10.2340\/00015555-3751","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"4620_CR42","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.jid.2023.04.005","volume":"143","author":"RD Mortlock","year":"2023","unstructured":"Mortlock RD, Ma EC, Cohen JM, Damsky W (2023) Assessment of treatment-relevant immune biomarkers in psoriasis and atopic dermatitis: toward personalized medicine in dermatology. J Invest Dermatol 143(8):1412\u20131422. https:\/\/doi.org\/10.1016\/j.jid.2023.04.005","journal-title":"J Invest Dermatol"},{"issue":"4","key":"4620_CR43","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/ced.13367","volume":"43","author":"NY Yoon","year":"2018","unstructured":"Yoon NY and others (2018) Simultaneous detection of barrier- and immune-related gene variations in patients with atopic dermatitis by reverse blot hybridization assay. Clin Exp Dermatol 43(4):430\u2013436. https:\/\/doi.org\/10.1111\/ced.13367","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"4620_CR44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/jdv.19506","volume":"38","author":"Y Renert-Yuval","year":"2024","unstructured":"Renert-Yuval Y and others (2024) Treat-to-target in dermatology: a scoping review and International Eczema Council survey on the approach in atopic dermatitis. J Eur Acad Dermatol Venereol 38(1):42\u201351. https:\/\/doi.org\/10.1111\/jdv.19506","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"4620_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","volume":"18","author":"AR Parra S\u00e1nchez","year":"2022","unstructured":"Parra S\u00e1nchez AR, Voskuyl AE, van Vollenhoven RF (2022) Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol 18(3):146\u2013157. https:\/\/doi.org\/10.1038\/s41584-021-00739-3","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"4620_CR46","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jaad.2023.01.053","volume":"89","author":"J Yeung","year":"2023","unstructured":"Yeung J and others (2023) Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: a Canadian perspective. J Am Acad Dermatol 89(2):372\u2013375. https:\/\/doi.org\/10.1016\/j.jaad.2023.01.053","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"4620_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/GELS9090753","volume":"9","author":"PI Siafaka","year":"2023","unstructured":"Siafaka PI, \u00d6zcan B\u00fclb\u00fcl E, Okur ME et al (2023) The application of nanogels as efficient drug delivery platforms for dermal\/transdermal delivery. Gels 9(9):753. https:\/\/doi.org\/10.3390\/GELS9090753","journal-title":"Gels"},{"issue":"1","key":"4620_CR48","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1080\/10717544.2021.1955042","volume":"28","author":"C Li","year":"2021","unstructured":"Li C, Obireddy SR, Lai WF (2021) Preparation and use of nanogels as carriers of drugs. Drug Deliv 28(1):1594\u20131602. https:\/\/doi.org\/10.1080\/10717544.2021.1955042","journal-title":"Drug Deliv"},{"key":"4620_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/GELS9040331","author":"G Alotaibi","year":"2023","unstructured":"Alotaibi G and others (2023) Nano-gels: recent advancement in fabrication methods for mitigation of skin cancer. Gels. https:\/\/doi.org\/10.3390\/GELS9040331","journal-title":"Gels"},{"issue":"10023","key":"4620_CR50","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N (2016) Atopic dermatitis. Lancet 387(10023):1109\u20131122. https:\/\/doi.org\/10.1016\/S0140-6736(15)00149-X","journal-title":"Lancet"},{"issue":"5","key":"4620_CR51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/1715163517710958","volume":"150","author":"ITY Wong","year":"2017","unstructured":"Wong ITY, Tsuyuki RT, Cresswell-Melville A et al (2017) Guidelines for the management of atopic dermatitis (eczema) for pharmacists. Can Pharm J 150(5):285\u2013297. https:\/\/doi.org\/10.1177\/1715163517710958","journal-title":"Can Pharm J"},{"issue":"8","key":"4620_CR52","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2174\/1567201817666200608145748","volume":"17","author":"N\u00dc Okur","year":"2020","unstructured":"Okur N\u00dc, Ya\u011fc\u0131lar AP, Siafaka PI (2020) Promising polymeric drug carriers for local delivery: the case of in situ gels. Curr Drug Deliv 17(8):675\u2013693. https:\/\/doi.org\/10.2174\/1567201817666200608145748","journal-title":"Curr Drug Deliv"},{"key":"4620_CR53","unstructured":"\u201cTreatment-Resistant Atopic Dermatitis in Adulthood: A Case Report | Cureus.\u201d"},{"key":"4620_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS24087557","author":"A Mesjasz","year":"2023","unstructured":"Mesjasz A, Ko\u0142kowski K, Wollenberg A, Trzeciak M (2023) How to understand personalized medicine in atopic dermatitis nowadays? Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS24087557","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4620_CR55","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1517\/14712598.2013.758708","volume":"13","author":"E Guttman-Yassky","year":"2013","unstructured":"Guttman-Yassky E, Dhingra N, Leung DYM (2013) New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther 13(4):549\u2013561. https:\/\/doi.org\/10.1517\/14712598.2013.758708","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"4620_CR56","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMOA1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA and others (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371(2):130\u2013139. https:\/\/doi.org\/10.1056\/NEJMOA1314768","journal-title":"N Engl J Med"},{"issue":"4","key":"4620_CR57","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/S40257-024-00859-Y","volume":"25","author":"AS Paller","year":"2024","unstructured":"Paller AS and others (2024) Dupilumab safety and efficacy up to 1 year in children aged 6 months to 5 years with atopic dermatitis: results from a phase 3 open-label extension study. Am J Clin Dermatol 25(4):655\u2013668. https:\/\/doi.org\/10.1007\/S40257-024-00859-Y","journal-title":"Am J Clin Dermatol"},{"issue":"15","key":"4620_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/JCM11154431","volume":"11","author":"A Tsiogka","year":"2022","unstructured":"Tsiogka A and others (2022) The JAK\/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: a systematic review. J Clin Med 11(15):4431. https:\/\/doi.org\/10.3390\/JCM11154431","journal-title":"J Clin Med"},{"issue":"4","key":"4620_CR59","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/J.JAAD.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K and others (2021) Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol 85(4):863\u2013872. https:\/\/doi.org\/10.1016\/J.JAAD.2021.04.085","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"4620_CR60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMOA1917006;WGROUP:STRING:MMS","volume":"383","author":"K Kabashima","year":"2020","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M (2020) Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med 383(2):141\u2013150. https:\/\/doi.org\/10.1056\/NEJMOA1917006;WGROUP:STRING:MMS","journal-title":"N Engl J Med"},{"issue":"1","key":"4620_CR61","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/PHARMACEUTICS15010164","volume":"15","author":"MR Donthi","year":"2023","unstructured":"Donthi MR, Munnangi SR, Krishna KV et al (2023) Nanoemulgel: a novel nano carrier as a tool for topical drug delivery. Pharmaceutics 15(1):164. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15010164","journal-title":"Pharmaceutics"},{"issue":"1","key":"4620_CR62","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/S12929-025-01161-7","volume":"32","author":"W Gonciarz","year":"2025","unstructured":"Gonciarz W and others (2025) Chitosan-based formulations for therapeutic applications. A recent overview. J Biomed Sci 32(1):62. https:\/\/doi.org\/10.1186\/S12929-025-01161-7","journal-title":"J Biomed Sci"},{"key":"4620_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/S12989-014-0038-4","author":"M Ilves","year":"2014","unstructured":"Ilves M et al (2014) Topically applied ZnO nanoparticles suppress allergen induced skin inflammation but induce vigorous IgE production in the atopic dermatitis mouse model. Part Fibre Toxicol. https:\/\/doi.org\/10.1186\/S12989-014-0038-4","journal-title":"Part Fibre Toxicol"},{"issue":"1","key":"4620_CR64","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12951-023-01924-0","volume":"21","author":"L Qiu","year":"2023","unstructured":"Qiu L and others (2023) Zn-MOF hydrogel: regulation of ROS-mediated inflammatory microenvironment for treatment of atopic dermatitis. J Nanobiotechnology 21(1):163. https:\/\/doi.org\/10.1186\/s12951-023-01924-0","journal-title":"J Nanobiotechnology"},{"issue":"4","key":"4620_CR65","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1166\/jbn.2007.049","volume":"3","author":"EB Souto","year":"2007","unstructured":"Souto EB, Almeida AJ, M\u00fcller RH (2007) Lipid nanoparticles (SLN\u00ae, NLC\u00ae) for cutaneous drug delivery: Structure, protection and skin effects. J Biomed Nanotechnol 3(4):317\u2013331. https:\/\/doi.org\/10.1166\/jbn.2007.049","journal-title":"J Biomed Nanotechnol"},{"key":"4620_CR66","unstructured":"Dhingra A (2026) Formulation and evaluation of diclofenac sodium-loaded solid lipid nanoparticles in ceramide cream for the treatment of atopic dermatitis. J Chem Heal Risks 15(5): 3335\u20133350"},{"issue":"7","key":"4620_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071927","volume":"15","author":"C Try","year":"1927","unstructured":"Try C and others (1927) \u201cPolymeric nanoparticles\u2019 accumulation in atopic dermatitis: clinical comparison between healthy, non-lesional, and lesional skin,\u201d. Pharmaceutics 15(7):1927. https:\/\/doi.org\/10.3390\/pharmaceutics15071927","journal-title":"Pharmaceutics"},{"key":"4620_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091454","author":"KCB Ferreira","year":"2021","unstructured":"Ferreira KCB, Valle ABCDS, Paes CQ et al (2021) Nanostructured lipid carriers for the formulation of topical anti-inflammatory nanomedicines based on natural substances. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13091454","journal-title":"Pharmaceutics"},{"key":"4620_CR69","doi-asserted-by":"publisher","DOI":"10.2174\/0122117385373434250705125526","author":"M Rezigue","year":"2025","unstructured":"Rezigue M, Bashatwah RM, Seetan KI, Aljabali AAA (2025) Nanocarriers in atopic dermatitis therapy: a comprehensive exploration. Pharm Nanotechnol. https:\/\/doi.org\/10.2174\/0122117385373434250705125526","journal-title":"Pharm Nanotechnol"},{"key":"4620_CR70","doi-asserted-by":"publisher","unstructured":"Ramachandran T, Mohanraj KG, Mary Martin T, MSK (2024) Enhanced wound healing with \u03b2-chitosan-zinc oxide nanoparticles: insights from zebrafish models. Cureus 16(9). https:\/\/doi.org\/10.7759\/CUREUS.69861","DOI":"10.7759\/CUREUS.69861"},{"key":"4620_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e39255","author":"DR Jaishi","year":"2024","unstructured":"Jaishi DR and others (2024) Plant-mediated synthesis of zinc oxide (ZnO) nanoparticles using Alnus nepalensis D. Don for biological applications. Heliyon. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e39255","journal-title":"Heliyon"},{"issue":"14","key":"4620_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/NANO14141182","volume":"14","author":"D Mutukwa","year":"2024","unstructured":"Mutukwa D, Taziwa RT, Khotseng L (2024) A review of plant-mediated ZnO nanoparticles for photodegradation and antibacterial applications. Nanomaterials 14(14):1182. https:\/\/doi.org\/10.3390\/NANO14141182","journal-title":"Nanomaterials"},{"issue":"3","key":"4620_CR73","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/1061186X.2022.2141755","volume":"31","author":"N Sabouni","year":"2023","unstructured":"Sabouni N and others (2023) Role of curcumin and its nanoformulations in the treatment of neurological diseases through the effects on stem cells. J Drug Target 31(3):243\u2013260. https:\/\/doi.org\/10.1080\/1061186X.2022.2141755","journal-title":"J Drug Target"},{"issue":"3","key":"4620_CR74","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3831\/KPI.2020.23.3.173","volume":"23","author":"Y Panahi","year":"2020","unstructured":"Panahi Y, Rastgar N, Zamani A, Sahebkar A (2020) Comparing the therapeutic effects of Aloe vera and olive oil combination cream versus topical betamethasone for atopic dermatitis: a randomized double-blind clinical trial. J Pharmacopunct 23(3):173. https:\/\/doi.org\/10.3831\/KPI.2020.23.3.173","journal-title":"J Pharmacopunct"},{"key":"4620_CR75","unstructured":"Fowler J, Nebus JA, Wallo W, Eichenfield L (2012) Colloidal oatmeal formulations as adjunct treatments in atopic dermatitis. J Drugs Dermatology"},{"key":"4620_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS19010173","author":"E Kim","year":"2018","unstructured":"Kim E and others (2018) Skin protective effect of epigallocatechin gallate. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS19010173","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4620_CR77","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/09546630310014369","volume":"14","author":"M Saeedi","year":"2003","unstructured":"Saeedi M, Morteza-Semnani K, Ghoreishi MR (2003) The treatment of atopic dermatitis with licorice gel. J Dermatolog Treat 14(3):153\u2013157. https:\/\/doi.org\/10.1080\/09546630310014369","journal-title":"J Dermatolog Treat"},{"key":"4620_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS24021498","author":"JH Yoon","year":"2023","unstructured":"Yoon JH, Kim MY, Cho JY (2023) Apigenin: a therapeutic agent for treatment of skin inflammatory diseases and cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS24021498","journal-title":"Int J Mol Sci"},{"key":"4620_CR79","doi-asserted-by":"publisher","first-page":"7382506","DOI":"10.1155\/2016\/7382506","volume":"2016","author":"MA Alzohairy","year":"2016","unstructured":"Alzohairy MA (2016) Therapeutics role of Azadirachta indica (Neem) and their active constituents in diseases prevention and treatment. Evid Based Complement Alternat Med 2016:7382506. https:\/\/doi.org\/10.1155\/2016\/7382506","journal-title":"Evid Based Complement Alternat Med"},{"key":"4620_CR80","unstructured":"Banerjee M, Debasrita, Suchismita C, Mallika (2025) Centella asiatica-derived compounds: applications in the prevention and treatment of skin disorders. 323\u2013329"},{"issue":"10","key":"4620_CR81","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1002\/PTR.7203","volume":"35","author":"S Banerjee","year":"2021","unstructured":"Banerjee S and others (2021) Bacosides from Bacopa monnieri extract: an overview of the effects on neurological disorders. Phytother Res 35(10):5668\u20135679. https:\/\/doi.org\/10.1002\/PTR.7203","journal-title":"Phytother Res"},{"key":"4620_CR82","doi-asserted-by":"crossref","unstructured":"Tanveer L, Batool S, Mubeen H, Shahid I (2025) Enhancing the therapeutic potential of FDA-approved ifosfamide and 5-fluorouracil through rational chemical modifications for endometrial cancer treatment. Med Oncol 42:281. https:\/\/pubmed.ncbi.nlm.nih.gov\/40560289\/","DOI":"10.1007\/s12032-025-02821-2"},{"key":"4620_CR83","doi-asserted-by":"crossref","unstructured":"Mubeen H, Rafiq N, Khan M, Jabeen S, Shoaib MW (2025) Toxicity assessment of doxycycline-aided artificial intelligence-assisted drug design targeting candidate 16S rRNA methyltransferase gene. BMC Pharmacol Toxicol 26:195. https:\/\/pubmed.ncbi.nlm.nih.gov\/41272886\/","DOI":"10.1186\/s40360-025-00875-6"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04620-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-026-04620-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04620-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:04:35Z","timestamp":1790712275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-026-04620-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":83,"alternative-id":["4620"],"URL":"https:\/\/doi.org\/10.1007\/s11845-026-04620-8","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article is a narrative review and does not involve human participants or animal experiments.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest related to this manuscript.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}